Organon & Co. (OGN) received a Neutral rating from analyst Navann Ty at BNP Paribas on April 29, 2026, reflecting caution in the current market environment. With the stock trading at $13.33, this rating suggests limited upside potential, as the average price target stands at $14. Investors should be mindful of this moderate outlook, which signals the need for careful assessment before making investment decisions.
Recent Price Action
In recent trading sessions, Organon’s stock has shown slight upward momentum, closing at $13.33—a modest increase of $0.01, or 0.08%. This figure reflects significantly reduced volatility compared to the broader market, with a beta of just 0.638. The stock’s 52-week range has been wide, reflecting a high of $16.99 and a low of $9.55. The recent surge in volume, which reached over 16 million shares against an average volume of approximately 5.8 million, points to increased investor interest, albeit at a cautious pace. This uptick may indicate a testing of resistance levels, as investors appear to search for cues to guide future movements amid prevailing uncertainty.
[chart type=’price’ value=’OGN’]
Short- and Long-Term Performance
Organon’s performance over the last month reveals a robust growth trajectory, with a 35.34% increase. However, the stock’s quarterly performance has been more subdued, showing only a 1.94% rise. Over the past year, Organon has suffered a notable decline of 41.53%, illustrating volatility associated with broader market trends and sector-specific challenges. Weekly volatility of 4.87% and monthly volatility of 4.24% suggest that while short-term movements have been positive, the stock is still experiencing fluctuation that investors should consider. The average trading volume has spiked in the last 10 days to approximately 30.2 million shares, indicative of amplified trading interest surrounding the stock.
[chart type=’performance’ value=’OGN’]
Earnings Analysis
Organon’s most recent earnings report showcases significant discrepancies between actual and expected performance. For the quarter ended November 10, 2025, the company reported an actual earnings per share (EPS) of $0.00061, a stark contrast to the estimated EPS of $0.93—a staggering surprise factor of -99.93%. This shortfall follows a previous quarter where Organon exceeded expectations slightly with an EPS of $1 against an estimate of $0.94, leading to a surprise of 6.38%. The volatility in earnings signals an urgent need for the company to respond effectively to its challenges to build investor confidence moving forward.
[chart type=’income-bar-chart’ value=’OGN’]
Analyst / Consensus View
Over the past 90 days, the consensus rating for Organon signals a cautious approach among analysts. The stock currently holds a total of three ratings: notably, there are no Buy ratings, two Hold ratings, and one Sell rating. The average price target, sitting at $12, indicates a downside potential from its current price. Notably, the highest target is $14 and the lowest at $8, suggesting differing viewpoints on the stock’s recovery trajectory. This mixed sentiment, expressed by BNP Paribas’ recent downgrade to Neutral, emphasizes the prevailing uncertainty among analysts regarding the company’s future prospects.
[chart type=’analyst-ratings’ value=’OGN’]
Stock Grading or Fundamental View
Organon has received a Stocks Telegraph Grade of 45, which reflects a moderately favorable assessment of the company’s overall health and investment profile. This score aggregates various financial metrics and market analyses, showcasing the company’s current position within its industry. While the score indicates some level of resilience, lower scores generally denote weak growth prospects or operational challenges that require careful management.
[chart type=’st-cards’ value=’OGN’]
Conclusion
For investors considering Organon & Co. (OGN), it is essential to approach this stock with caution. The current Neutral rating from analysts, combined with significant discrepancies in earnings estimates and a mixed consensus view, makes it more suitable for defensive investors or those with a longer investment horizon willing to weather volatility. However, investors should remain alert to the structural challenges faced by the company. Potential risk factors include continued earnings miss, competitive pressures, and broader market fluctuations. As investment conditions evolve, Organon may present opportunities for value-oriented investors, particularly if it can stabilize its performance in upcoming quarters.